We are a biopharmaceutical company committed to developing targeted therapies
through biomarker-driven insights to provide substantial improvements in patient
outcomes where significant unmet medical needs exist. Our proprietary platform
has delivered unique insights into cancer and related disease. Our strategy is
to leverage these biomarker insights and partner resources to advance the
development of our clinical pipeline. As further described below, we currently
are exploring partnership opportunities to fund the further development of three
of our four development programs, including our lead program for tivozanib.
Our development programs, which seek to advance our clinical stage assets, are
* Tivozanib: In 2006, we acquired exclusive rights to develop and
commercialize tivozanib, outside of Asia pursuant to a license agreement
we entered into with Kirin Brewery Co. Ltd.